» Articles » PMID: 18462102

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group...

Abstract

Background: Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies.

Methods: After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved.

Results: The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only.

Conclusions: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.

Citing Articles

Diagnosis of Aspergillus Osteomyelitis of the Clivus and Sella Turcica in a Patient With Type 2 Diabetes and a History of Prolonged Intranasal Corticosteroid Use.

Patel R, Kholodovych V, Tellado-Fente M, Vittor A Cureus. 2025; 17(2):e78779.

PMID: 40070624 PMC: 11896577. DOI: 10.7759/cureus.78779.


Airway-centered invasive pulmonary aspergillosis featuring histopathologic fruiting bodies in an immunocompetent patient with a rare incidental finding of thyroid gland Schwannoma: a case report.

Majeed I, Aziz S, Khan Z, Arnold F BMC Infect Dis. 2025; 25(1):344.

PMID: 40069656 PMC: 11899796. DOI: 10.1186/s12879-025-10694-z.


Early prediction of invasive fungal infection risk in acute-on-chronic liver failure: a prediction model based on admission indicators.

Yang X, Li J, Yang Y, Zhang L, Dan X, Cai D BMC Microbiol. 2025; 25(1):131.

PMID: 40069589 PMC: 11900632. DOI: 10.1186/s12866-025-03819-6.


Arora-Nagarkar Prognostic Classification for Rhinocerebral Mucormycosis: A Novel Prognostic Classification System.

Arora R, Aggarwal A, Nagarkar N, Thangaraju P, Keche A, Bodhey N Indian J Otolaryngol Head Neck Surg. 2025; 77(1):412-416.

PMID: 40066399 PMC: 11890712. DOI: 10.1007/s12070-024-05210-9.


Outcome Analysis of Breakthrough Invasive Aspergillosis on Anti-Mold Azole Prophylaxis and Treatment: 30-Year Experience in Hematologic Malignancy Patients.

Dagher H, Chaftari A, Haddad A, Jiang Y, Shrestha J, Sherchan R J Fungi (Basel). 2025; 11(2).

PMID: 39997454 PMC: 11856094. DOI: 10.3390/jof11020160.


References
1.
Ostrosky-Zeichner L, Alexander B, Kett D, Vazquez J, Pappas P, Saeki F . Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005; 41(5):654-9. DOI: 10.1086/432470. View

2.
Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge R . Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004; 39(2):199-205. DOI: 10.1086/421944. View

3.
Ullmann A, Lipton J, Vesole D, Chandrasekar P, Langston A, Tarantolo S . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356(4):335-47. DOI: 10.1056/NEJMoa061098. View

4.
Maertens J, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou K . Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis. 2007; 44(10):1329-36. DOI: 10.1086/514349. View

5.
Donnelly J . Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006; 42(4):487-9. DOI: 10.1086/499818. View